Laboratorio Pablo Cassará S.R.L.   Report issue

For profit Phase 1 Phase 3
Founded: Buenos Aires Argentina (1948)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2009
NCT01729663
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Laboratorio Pablo Cassara S.R.L. | Laboratorio Pablo Cassará S.R.L.

Active Ingredients

Drugs in Phase 3 Trials (4)

bacille calmette-guerin (1 trial)

csf470 (1 trial)

Filgrastim (neupogen) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

Drugs in Phase 1 Trials (1)

arvac-cg (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5